Curis (CRIS) News Today → Don’t buy a single NVIDIA share before you see this... (From Behind the Markets) (Ad) Free CRIS Stock Alerts $10.36 -0.27 (-2.54%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Curis’s Emavusertib Following Promising Leukemia Study ResultsMay 15, 2024 | marketbeat.comCuris (NASDAQ:CRIS) Receives Buy Rating from Truist FinancialTruist Financial reaffirmed a "buy" rating and set a $26.00 target price on shares of Curis in a research note on Wednesday.May 14, 2024 | prnewswire.comCuris Announces Additional Data from TakeAim Leukemia StudyMay 10, 2024 | prnewswire.comCuris to Present Updated Data from the TakeAim Leukemia StudyMay 10, 2024 | marketbeat.comQ2 2024 Earnings Forecast for Curis, Inc. Issued By HC Wainwright (NASDAQ:CRIS)Curis, Inc. (NASDAQ:CRIS - Free Report) - Equities researchers at HC Wainwright increased their Q2 2024 earnings per share estimates for Curis in a research report issued on Wednesday, May 8th. HC Wainwright analyst E. White now anticipates that the biotechnology company will post earnings of ($2May 8, 2024 | markets.businessinsider.comCuris Buy Rating Affirmed on Strong Earnings and Promising Emavusertib TrialsMay 8, 2024 | finance.yahoo.comCuris, Inc. (NASDAQ:CRIS) Q1 2024 Earnings Call TranscriptMay 8, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Curis (NASDAQ:CRIS)HC Wainwright restated a "buy" rating and issued a $26.00 price target on shares of Curis in a report on Wednesday.May 8, 2024 | marketbeat.comCuris (NASDAQ:CRIS) Announces Quarterly Earnings Results, Misses Expectations By $0.11 EPSCuris (NASDAQ:CRIS - Get Free Report) released its earnings results on Tuesday. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.94) by ($0.11). Curis had a negative return on equity of 169.22% and a negative net margin of 473.04%. During the same period last year, the business earned ($2.40) EPS.May 7, 2024 | investorplace.comCRIS Stock Earnings: Curis Beats EPS, Misses Revenue for Q1 2024May 7, 2024 | finanznachrichten.deCuris, Inc.: Curis Provides First Quarter 2024 Business UpdateMay 7, 2024 | markets.businessinsider.comCuris Inc Q1 Loss beats estimatesMay 7, 2024 | washingtonpost.comCuris: Q1 Earnings SnapshotMay 7, 2024 | prnewswire.comCuris Provides First Quarter 2024 Business UpdateApril 30, 2024 | prnewswire.comCuris to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024April 23, 2024 | finance.yahoo.comCuris, Inc. (CRIS)April 18, 2024 | finance.yahoo.comCuris, Inc. (CRIS) Interactive Stock Chart - Yahoo FinanceApril 9, 2024 | marketbeat.comCuris (NASDAQ:CRIS) Stock Passes Above Two Hundred Day Moving Average of $10.49Curis (NASDAQ:CRIS) Share Price Crosses Above 200-Day Moving Average of $10.49April 5, 2024 | prnewswire.comCuris Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)April 4, 2024 | prnewswire.comCuris to Present at Upcoming Healthcare Conferences in AprilApril 2, 2024 | prnewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Curis, Inc. (NASDAQ: CRIS)March 30, 2024 | marketbeat.comCuris, Inc. (NASDAQ:CRIS) Sees Large Drop in Short InterestCuris, Inc. (NASDAQ:CRIS - Get Free Report) was the recipient of a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 47,900 shares, a drop of 14.5% from the February 29th total of 56,000 shares. Approximately 0.8% of the shares of the company are sold short. Based on an average daily trading volume, of 35,000 shares, the days-to-cover ratio is presently 1.4 days.March 28, 2024 | finance.yahoo.comCuris, Inc. (CRIS) Stock Historical Prices & Data - Yahoo FinanceMarch 22, 2024 | marketbeat.comCitigroup Inc. Sells 1,745,553 Shares of Curis, Inc. (NASDAQ:CRIS)Citigroup Inc. lowered its holdings in shares of Curis, Inc. (NASDAQ:CRIS - Free Report) by 95.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 91,871 shares of the biotechnology company's stock after selMarch 21, 2024 | marketbeat.comCuris (NASDAQ:CRIS) Shares Cross Above Two Hundred Day Moving Average of $10.26Curis (NASDAQ:CRIS) Stock Price Crosses Above 200-Day Moving Average of $10.26March 5, 2024 | marketbeat.comKingdon Capital Management L.L.C. Sells 2,215,274 Shares of Curis, Inc. (NASDAQ:CRIS)Kingdon Capital Management L.L.C. trimmed its holdings in Curis, Inc. (NASDAQ:CRIS - Free Report) by 87.8% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 309,150 shares of the biotechnology company's stock after selling 2,215,274 shares duringMarch 4, 2024 | marketbeat.comCuris, Inc. (NASDAQ:CRIS) Shares Sold by Citigroup Inc.Citigroup Inc. cut its position in Curis, Inc. (NASDAQ:CRIS - Free Report) by 95.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 91,871 shares of the biotechnology company's stock after selling 1,745,553 sFebruary 24, 2024 | benzinga.comCuris Stock (NASDAQ:CRIS) Dividends: History, Yield and DatesFebruary 22, 2024 | benzinga.comCuris Stock (NASDAQ:CRIS), Analyst Ratings, Price Targets, PredictionsFebruary 12, 2024 | marketbeat.comBleichroeder LP Has $165,000 Holdings in Curis, Inc. (NASDAQ:CRIS)Bleichroeder LP reduced its holdings in Curis, Inc. (NASDAQ:CRIS - Free Report) by 90.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 24,999 shares of the biotechnology company's stock after selling 225,001 shares during the quarter. BlFebruary 10, 2024 | msn.comCuris Inc. Is Worried About This – Should You Be Worried Too?February 9, 2024 | finance.yahoo.comCuris, Inc. (NASDAQ:CRIS) Q4 2023 Earnings Call TranscriptFebruary 9, 2024 | marketbeat.comCuris (NASDAQ:CRIS) Issues Earnings Results, Misses Expectations By $0.12 EPSCuris (NASDAQ:CRIS - Get Free Report) announced its quarterly earnings results on Thursday. The biotechnology company reported ($2.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.91) by ($0.12). Curis had a negative return on equity of 135.38% and a negative net margin of 460.45%. The firm had revenue of $2.70 million for the quarter, compared to analysts' expectations of $2.95 million. During the same period last year, the company posted ($2.40) earnings per share.February 8, 2024 | finanznachrichten.deCuris, Inc.: Curis Provides Fourth Quarter 2023 Business UpdateFebruary 8, 2024 | markets.businessinsider.comCuris Inc Q4 sales declineFebruary 8, 2024 | finance.yahoo.comCuris Provides Fourth Quarter 2023 Business UpdateFebruary 7, 2024 | benzinga.comCuris's Earnings: A PreviewFebruary 2, 2024 | marketbeat.comCuris (CRIS) to Release Earnings on ThursdayCuris (NASDAQ:CRIS) will be releasing earnings before the market opens on Thursday, February 8, Zacks reports.February 1, 2024 | finance.yahoo.comCuris to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024January 22, 2024 | finance.yahoo.comCuris Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)December 18, 2023 | finance.yahoo.comCuris, Inc. (NASDAQ:CRIS) Surges 54% Yet Its Low P/S Is No Reason For ExcitementDecember 12, 2023 | markets.businessinsider.comBuy Rating on Curis Backed by Promising Clinical Trials and Strategic ExpansionDecember 12, 2023 | finance.yahoo.comCuris Announces Initial Combination Study Data from its TakeAim Lymphoma StudyDecember 11, 2023 | finance.yahoo.comCuris Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH ConferenceDecember 6, 2023 | markets.businessinsider.comPositive Buy Rating for Curis Stock Driven by Emavusertib’s Clinical Promise and Revenue PotentialDecember 6, 2023 | finance.yahoo.comCuris Announces Three Presentations at ASHDecember 5, 2023 | markets.businessinsider.comCuris Inks Deal With Florida University For Emavusertib/Pembrolizumab Combination Study In MelanomaDecember 5, 2023 | finance.yahoo.comCuris Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in MelanomaNovember 18, 2023 | morningstar.comCuris Inc CRISNovember 18, 2023 | msn.comTruist Securities Initiates Coverage of Curis (CRIS) with Buy Recommendation Get Curis News Delivered to You Automatically Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter. Email Address SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. CRIS Media Mentions By Week CRIS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRIS News Sentiment▼1.880.79▲Average Medical News Sentiment CRIS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRIS Articles This Week▼11▲CRIS Articles Average Week Get Curis News Delivered to You Automatically Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Sangamo Therapeutics News Today X4 Pharmaceuticals News Today Agenus News Today Turnstone Biologics News Today Protara Therapeutics News Today Ikena Oncology News Today LENZ Therapeutics News Today Entera Bio News Today Genenta Science News Today CEL-SCI News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRIS) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProDems have chosen Biden replacement?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is about to pass AppleWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
